

Arguments/ Remarks

Claims 108-115, 123, 131-136 are pending. Claims 112-113, 115, 125-130 have been withdrawn in light of the prior issued restriction requirement. Claims 1-107 and 116-122, 124 have been cancelled. Accordingly, claims 108-111, 114, 123, 131-136 are presently pending and under Examination. All claims stand free of the art.

Applicants have previously elected, for purposes of initial Examination, the hybridoma species 1F2 having ATCC accession no. PTA-5959. Applicants prior-filed Replay to the Official Action of November 30, 2007, provided a Verified Statement of co-inventor Maria Concetta Veri establishing the facts of this Deposit.

Applicants have requested rejoinder of the withdrawn claims and consideration of the Allowability of the full scope of the presented claims. In order to advance prosecution of such scope, Applicants herewith submit a Verified Statement of co-inventor Maria Concetta Veri establishing the facts of the deposits of the four additional clones recited in the claims:

1. Clone 1D5 having ATCC Accession No. PTA-5958;
2. Clone 2E1 having ATCC Accession No. PTA-5961;
3. Clone 2H9 having ATCC Accession No. PTA-5962; and
4. Clone 2D11 having ATCC Accession No. PTA-5960.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. §121. The Application is believed to be in condition for further Examination and early notice of favorable action is respectfully requested.

Should the Examiner have any remaining questions regarding the subject invention or its patentability, Applicants encourage the Examiner to contact the undersigned.

Date: **March 4, 2008**
Edell, Shapiro & Finnan, LLC
1901 Research Boulevard, Suite 400
Rockville, MD 20850
Telephone: (301) 424-3640
Facsimile: (301) 762-4056

Respectfully Submitted,

/Jeffrey I. Auerbach/
Jeffrey I. Auerbach
Registration No. 32,680
Attorney for Assignee

Customer No. **66522**

In The United States Patent and Trademark Office

In re application of:
Koenig, Scott *et al.*

Appl. No. **10/643,857**

Filed: **August 14, 2003**

For: **FcγRIIB-Specific Antibodies
and Methods of Use Thereof**

Art Unit: **1644**

Examiner: **Dahle, Chun Wu**

Atty. Docket: **1301.0019C**

Confirmation No.: **1191**

Second Verified Statement of Maria Concetta Veri

Filed via EFS-Web
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Maria Concetta Veri, hereby declare:


1. I am a co-inventor of the invention claimed in the above-described patent application, and have personal knowledge of the matters related in this Declaration.
2. On February 28, 2008, I submitted a Verified Statement relating to the Deposit of the hybridoma cell lines **1F2** (ATCC Accession No. PTA-5959). I make this Second Verified Statement to address the Deposits of the hybridoma cell lines: **1D5**, **2D11**, **2E1** and **2H9**, which are described in the above-identified patent application.
3. Each of the hybridoma cell lines: **1D5**, **2D11**, **2E1** and **2H9**, which are described in the above-identified patent application were produced prior to the filing date of the above-identified patent application.

4. On May 4, 2004, I deposited each of the hybridoma cell lines **1D5**, **2D11**, **2E1** and **2H9** with the American Type Culture Collection (ATCC) under the terms of the Budapest Treaty. I have enclosed a copy of the original Deposit Forms as evidence of the May 4, 2004 deposit. The deposited hybridomas were found to be viable by the ATCC and were accorded ATCC Accession Nos.: PTA-5958 (cell line **1D5**); PTA-5960 (cell line **2D11**); PTA-5961 (cell line **2E1**); and PTA-5962 (cell line **2H9**). I enclose the certificate of viability for these cell lines and for PTA-5959 (cell line **1F2**).
5. From a time prior to the filing date of the above-identified patent application to May 4, 2004, each of the hybridoma cell lines **1D5**, **2D11**, **2E1** and **2H9** were kept under my personal supervision and control in a liquid nitrogen freezer. To my knowledge no other person accessed these cell lines during this period.
6. Each of the hybridoma cell lines: **1D5**, **2D11**, **2E1** and **2H9**, which are described in the above-identified patent application is the same cell line that was deposited with the American Type Culture Collection on May 4, 2004 and accorded ATCC Accession Nos.: PTA-5958 (cell line **1D5**); PTA-5960 (cell line **2D11**); PTA-5961 (cell line **2E1**); and PTA-5962 (cell line **2H9**).
7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of
the application or any patent issued thereon.



Maria Concetta Veri



Date



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection
P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- ☐ Microorganism – the complete scientific name including genus and species plus the source of the material
☐ Virus – the name, whether plant or animal, and source including geographic location
☒ Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
☐ Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
☐ Consortia or mixed culture – the identity of each component of the mixture
☐ Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical

HYBRIDOMA F₂ RIIL TRANSGENIC HIC WERE IMMUNIZED WITH MANNANIAN
EXPRESSED EXTRACELLULAR PORTION OF E₁ RIIL. LYMPHOCYTES FROM THE
IMMUNIZED HIC WERE FUSED WITH H-1 MYELOMA CELLS TO IMMORTALIZE THE

2. Strain designation* (i.e., number, symbols, etc.) 1D5
 *The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? ☒ Yes ☐ No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?
☐ Yes ☒ No
 If yes, please indicate ATCC designation.

5. Is this deposit a mixture of microorganisms or cells? ☐ Yes ☒ No
 If yes, please describe:

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DUPRECO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL CALF
SERUM, 2mM GLUTAMINE AND 50µg/ml GENTAMICIN. CELLS HAVE BEEN
FROZEN (10⁶ CELLS/IAL) IN FETAL CALF SERUM CONTAINING 10%
DMSO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS.

- a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? ☒ Yes ☐ No
 If yes, please list the antibiotics: GENTAMICIN (50µg/ml)

- b. If deposit is a hybridoma, what is the isotype of the antibody produced? mouse IgG 1

8. Safety: Is this strain hazardous to humans? NO Animals? NO Plants? NO

If yes, what is the recommended biosafety level for working with this strain?

(Refer to Biosafety in Microbiological and Biomedical Laboratories, 4th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC; U.S. Government Printing Office; 1999. The entire text is available online at www.cdc.gov/cdc/ehs/biosfty/bml4/bml4toc.htm.)

9. Regulatory Compliance:

- a. Was the material derived from a human? ☐ Yes ☒ No
If yes, was an IRB-approved consent form (human subjects) obtained? ☐ Yes ☒ No
- b. Was this material obtained from wildlife? ☐ Yes ☒ No
If yes, please indicate genus and species and whether wild or captive bred. _____
- c. Is work performed at your facility with exotic viruses affecting livestock and avian species? ☐ Yes ☒ No
- d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED - ORIGIN: UNITED STATES - MYCOPLASMA, VIRUS, BACTERIOPHAGE AND ENDOTOXIN TESTED (INVITROGEN CORPORATION).

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

- a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. ☐ Yes ☒ No
- b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? ☐ Yes ☒ No
If "yes," please state which countries: _____

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a][2]).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. PanigotFax: 301-251-5321 Phone: 301-354-0686 E-mail: panigot.j@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____

Check No. _____

Credit Card number. _____

☐ MasterCard ☐ VISA ☐ American Express

Exp. Date: _____

Name shown on card: _____

(Please print clearly or type)

Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn MaracicBilling Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6702Phone: (212) 790-6417 Fax: (212) 869-9741Do you have a current ATCC account number? ☒ Yes ☐ NoIf Yes: ATCC Account Number = 178147If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Gardline F. Balduino, Esq.
Jones Day, 222 E. 41st Street
New York, NY 10017-6702 (Ref. Docket or Case No. 11183-013-999)

14. **MUST BE COMPLETED.** Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Parigot Joseph E. Parigot 5/14/04
Printed Name Signature Date

Address: MacroGenics, Inc., 1500 East Gule Drive, Rockville, MD 20850

Phone: (301) 354-0686 Fax: (301) 851-5321 E-mail: parigot.j@macrogenics.com

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax (703) 365-2745
E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION _____ REC'D _____ V.T. RESULT _____

ATCC® is a registered trademark of the American Type Culture Collection.

Form No. PTF001.02, effective 4/8/03

Page 3 of 3



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection

P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- ☐ Microorganism – the complete scientific name including genus and species plus the source of the material
☐ Virus – the name, whether plant or animal, and source including geographic location
☒ Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
☐ Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
☐ Consortia or mixed culture – the identity of each component of the mixture
☐ Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

HYBRIDOMA CELL LINE TRANSGENIC H1G WERE IMMUNIZED WITH MANNAIATM EXPRESSED EXTRACELLULAR PORTION OF AFB1/ITB. LYMPHOCYTES FROM THE IMMUNIZED H1G WERE FUSED WITH H1-1 MYELOMA CELLS TO IMMORTALIZE

2. Strain designation* (i.e., number, symbols, etc.) 2D11
 *The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? ☒ Yes ☐ No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?
☐ Yes ☒ No
 If yes, please indicate ATCC designation. _____

5. Is this deposit a mixture of microorganisms or cells? ☐ Yes ☒ No
 If yes, please describe: _____

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DIAGNO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL CALF SERUM 800µG GENTAMINE AND 500µg/ml GENTAMICIN. CELLS HAVE BEEN FROZEN (10⁶ cells/100µl) IN FETAL CALF SERUM (GIBCO) 10% DMSO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS

- a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? ☒ Yes ☐ No
 If yes, please list the antibiotics: GENTAMICIN (500µg/ml)

- b. If deposit is a hybridoma, what is the isotype of the antibody produced? murine IgG1

8. Safety: Is this strain hazardous to humans? NO Animals? NO Plants? NO

If yes, what is the recommended biosafety level for working with this strain? _____

(Refer to Biosafety in Microbiological and Biomedical Laboratories, 4th ed. HHS Publication No. (CDC) 69-8395, U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC; U.S. Government Printing Office; 1999. The entire text is available online at www.cdc.gov/od/ahq/biosafety/bml4/bml4toc.htm.)

9. Regulatory Compliance:

- a. Was the material derived from a human? ☐ Yes ☒ No
If yes, was an IRB-approved consent form (human subjects) obtained? ☐ Yes ☒ No
- b. Was this material obtained from wildlife? ☐ Yes ☒ No
If yes, please indicate genus and species and whether wild or captive bred. _____
- c. Is work performed at your facility with exotic viruses affecting livestock and avian species? ☐ Yes ☒ No
- d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED ORIGIN: UNITED STATES
MYCOPLASMA VIRUS BACTERIOPHAGE AND ENDOTOXIN TESTED
(INVITROGEN CORPORATION)

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

- a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. ☐ Yes ☒ No
- b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? ☐ Yes ☒ No
If "yes," please state which countries: _____

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a](2)).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Panigot
Fax: 301-251-5321 Phone: 301-354-0686 E-mail: panigot@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____ Check No. _____
Credit Card number. _____ ☐ MasterCard ☐ VISA ☐ American Express
Exp. Date: _____ Name shown on card: _____
(Please print clearly or type)
Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Maracic
Billing Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6702
Phone: (212) 190-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? ☒ Yes ☐ No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Germine F. Baldwin, Esq.

Jones Day, 222 E. 41st Street

New York, NY 10017-6702

(Ref: Docket or Case No. 11183-013-999)

14. **MUST BE COMPLETED.** Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Panigot

Printed Name

Joseph E. Panigot

Signature

5/4/04

Date

Address: MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850

Phone: (301) 354-0686

Fax: ³⁰¹(301) 251-5321

E-mail: panigot.j@macrogenics.com

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax: (703) 365-2745

E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION

REC'D

V.T. RESULT

ATCC® is a registered trademark of the American Type Culture Collection.

Form No. PTF001.00, effective 4/8/03

Page 3 of 3



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection

P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- ☐ Microorganism – the complete scientific name including genus and species plus the source of the material
☐ Virus – the name, whether plant or animal, and source including geographic location
☒ Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
☐ Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
☐ Consortia or mixed culture – the identity of each component of the mixture
☐ Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

HYBRIDOMA Fc γ RIIA TRANSGENIC MICE WERE IMMUNIZED WITH MANNANIN
 EXPRESSED EXTRACELLULAR PORTION OF Fc γ RIIB. LYMPHOCYTES FROM THE IMMUNIZED
 MICE WERE FUSED WITH H1.1 MYELOMA CELLS TO IMMORTALIZE THEM.

2. Strain designation* (i.e., number, symbols, etc.) 2E1
 *The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? ☒ Yes ☐ No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?
☐ Yes ☒ No
 If yes, please indicate ATCC designation.

5. Is this deposit a mixture of microorganisms or cells? ☐ Yes ☒ No
 If yes, please describe:

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DULBECCO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL CALF
 SERUM, 0.1MM GLUTAMINE AND 1000IU GENTAMICIN. CELLS HAVE BEEN
 FROZEN (10⁶ CELLS/VIAL) IN FETAL CALF SERUM CONTAINING 10% DMSO
 AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS

- a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? ☒ Yes ☐ No
 If yes, please list the antibiotics: GENTAMICIN (100µg/ml)

- b. If deposit is a hybridoma, what is the isotype of the antibody produced? murine IgG1

8. Safety: Is this strain hazardous to humans? No Animals? No Plants? No

If yes, what is the recommended biosafety level for working with this strain?

(Refer to Biosafety in Microbiological and Biomedical Laboratories, 4th ed. HHS Publication No. (CDC) 93-8395, U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC; U.S. Government Printing Office, 1999. The entire text is available online at www.cdc.gov/odnh/biosafety/bmbld/bmbld4toc.html.)

9. Regulatory Compliance:

- a. Was the material derived from a human? ☐ Yes ☒ No
If yes, was an IRB-approved consent form (human subjects) obtained? ☐ Yes ☒ No
- b. Was this material obtained from wildlife? ☐ Yes ☒ No
If yes, please indicate genus and species and whether wild or captive bred. _____
- c. Is work performed at your facility with exotic viruses affecting livestock and avian species? ☐ Yes ☒ No
- d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED, ORIGIN: UNITED STATES.
MYXOPLASMA VIRUS, BACTERIOPHAGE ANTIENDOTOXIN TESTED (INVITROGEN CORPORATION).

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

- a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. ☐ Yes ☒ No
- b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? ☐ Yes ☒ No
If "yes," please state which countries: _____

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a][2]).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Panigot
Fax: 301-251-9321 Phone: 301-354-0666 E-mail: panigot.j@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____ Check No. _____
Credit Card number. _____ ☐ MasterCard ☐ VISA ☐ American Express
Exp. Date: _____ Name shown on card: _____ (Please print clearly or type)
Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Maracic
Billing Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6702
Phone: (212) 790-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? ☒ Yes ☐ No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Geraldine F. Baldwin, Esq.

Jones Day, 222 E. 41st Street

New York, NY 10017-6702

(Ref: Docket or Case No. 11183-013-999)

14. **MUST BE COMPLETED.** Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Parigot

Printed Name

Signature

Date

5/4/04

Address: MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850

Phone: (301) 354-0686

Fax: (301) 251-5321

E-mail: parigot.j@macrogenics.co

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax (703) 365-2745

E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION _____ REC'D _____ V.T. RESULT _____

ATCC® is a registered trademark of the American Type Culture Collection.

Form No. PTF001.00, effective 4/8/03

Page 3 of 3



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection

P.O. Box 1549

Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- ☐ Microorganism – the complete scientific name including genus and species plus the source of the material
☐ Virus – the name, whether plant or animal, and source including geographic location
☒ Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
☐ Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
☐ Consortia or mixed culture – the identity of each component of the mixture
☐ Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

HYBRIDOMA FcγRIIA TRANSGENIC MICE WERE IMMUNIZED WITH KAHNLIAN EXPRESSED EXTRACELLULAR PORTION OF FcγRIIB. LYMPHOCYTES FROM THE IMMUNIZED MICE WERE FUSED WITH HL1 MYELOMA CELLS TO IMMORTALIZE THEM.

2. Strain designation* (i.e., number, symbols, etc.) 2H9

*The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? ☒ Yes ☐ No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?

☐ Yes ☒ No

If yes, please indicate ATCC designation.

5. Is this deposit a mixture of microorganisms or cells? ☐ Yes ☒ No

If yes, please describe:

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DULBECCO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL CALF SERUM, 2mM GLUTAMINE AND 50μg/ml of GENTAMICIN. CELLS HAVE BEEN FROZEN (10⁶ CELLS/VIAL) IN FETAL CALF SERUM CONTAINING 10% OF DMSO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS

a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? ☒ Yes ☐ No

If yes, please list the antibiotics: GENTAMICIN (50μg/ml)

b. If deposit is a hybridoma, what is the isotype of the antibody produced? mIgG2a

8. Safety: Is this strain hazardous to humans? NO Animals? NO Plants? NO

If yes, what is the recommended biosafety level for working with this strain?

(Refer to Biosafety in Microbiological and Biomedical Laboratories, 4th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC: U.S. Government Printing Office, 1999. The entire text is available online at www.cdc.gov/od/ohs/biosfty/bmlb4/bmlb4toc.htm.)

9. Regulatory Compliance:

- a. Was the material derived from a human? ☐ Yes ☒ No
If yes, was an IRB-approved consent form (human subjects) obtained? ☐ Yes ☐ No
- b. Was this material obtained from wildlife? ☐ Yes ☒ No
If yes, please indicate genus and species and whether wild or captive bred. _____
- c. Is work performed at your facility with exotic viruses affecting livestock and avian species? ☐ Yes ☒ No
- d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED, ORIGIN: UNITED STATES, MYCOPLASMA VIRUS, BACTERIOPHAGE, ENDOTOXIN TESTED (INVITROGEN CORPORATION)

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

- a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. ☐ Yes ☒ No
- b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? ☐ Yes ☒ No
If "yes," please state which countries: _____

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a][2]).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Panigot
Fax: 301-251-5321 Phone: 301-354-0686 E-mail: panigot.j@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____ Check No. _____
Credit Card number. _____ ☐ MasterCard ☐ VISA ☐ American Express
Exp. Date: _____ Name shown on card: _____
Signature of card holder _____ (Please print clearly or type)

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Maracic
Billing Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6702
Phone: (212) 790-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? ☒ Yes ☐ No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Gemkline F. Baldwin, Esq.

Jones Day 222 E. 41st Street

New York, NY 10017-6702

(Ref: Docket or Case No. 11183-013-999)

14. **MUST BE COMPLETED.** Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Panigot

Printed Name

Joseph E. Panigot

Signature

5/4/06

Date

Address: MacroGenics, Inc., 1500 East Gude Dr., Rockville, MD 20850

Phone: (301) 354-2666

Fax: (301) 251-5321

E-mail: panigot.j@macrogenics.com

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax: (703) 365-2745

E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION

DTA-5962

REC'D

5/7/04

V.T. RESULT

5/6/04

ATCC® is a registered trademark of the American Type Culture Collection.

**BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE****INTERNATIONAL FORM****RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.**

To: (Name and Address of Depositor or Attorney)

MacroGenics, Inc.
Joseph E. Panigot
1500 East Gude Drive
Rockville, MD 20850

Deposited on Behalf of: MacroGenics, Inc.

Identification Reference by Depositor:Hybridoma: 1D5
Hybridoma: 1F2
Hybridoma: 2D11
Hybridoma: 2E1
Hybridoma: 2H9**Patent Deposit Designation**PTA-5958
PTA-5959
PTA-5960
PTA-5961
PTA-5962

The deposits were accompanied by: a scientific description, a proposed taxonomic description indicated above. The deposits were received May 7, 2004 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.


If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested May 25, 2004. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:


Marie Harris, Patent Specialist, ATCC Patent DepositoryDate: June 26, 2004cc: Geraldine F Baldwin, Esq.
Docket or Case No.: 11183-013-999